These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 23856031)

  • 21. Inhibition of RET tyrosine kinase by SU5416.
    Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
    J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
    Wang M; Naganna N; Sintim HO
    Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
    Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
    Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting RET for thyroid cancer therapy.
    Lanzi C; Cassinelli G; Nicolini V; Zunino F
    Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
    Huang Q; Schneeberger VE; Luetteke N; Jin C; Afzal R; Budzevich MM; Makanji RJ; Martinez GV; Shen T; Zhao L; Fung KM; Haura EB; Coppola D; Wu J
    Mol Cancer Ther; 2016 Oct; 15(10):2521-2529. PubMed ID: 27496134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and characterization of RET fusions in advanced colorectal cancer.
    Le Rolle AF; Klempner SJ; Garrett CR; Seery T; Sanford EM; Balasubramanian S; Ross JS; Stephens PJ; Miller VA; Ali SM; Chiu VK
    Oncotarget; 2015 Oct; 6(30):28929-37. PubMed ID: 26078337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
    Chen ZH; Yu YP; Tao J; Liu S; Tseng G; Nalesnik M; Hamilton R; Bhargava R; Nelson JB; Pennathur A; Monga SP; Luketich JD; Michalopoulos GK; Luo JH
    Gastroenterology; 2017 Oct; 153(4):1120-1132.e15. PubMed ID: 28245430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
    Kim DW; Jo YS; Jung HS; Chung HK; Song JH; Park KC; Park SH; Hwang JH; Rha SY; Kweon GR; Lee SJ; Jo KW; Shong M
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4070-6. PubMed ID: 16849418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
    Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
    BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor Activity of RXDX-105 in Multiple Cancer Types with
    Li GG; Somwar R; Joseph J; Smith RS; Hayashi T; Martin L; Franovic A; Schairer A; Martin E; Riely GJ; Harris J; Yan S; Wei G; Oliver JW; Patel R; Multani P; Ladanyi M; Drilon A
    Clin Cancer Res; 2017 Jun; 23(12):2981-2990. PubMed ID: 28011461
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
    Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway.
    Lin C; Wang S; Xie W; Zheng R; Gan Y; Chang J
    Oncotarget; 2016 Sep; 7(37):59236-59244. PubMed ID: 27494860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
    Drilon A; Fu S; Patel MR; Fakih M; Wang D; Olszanski AJ; Morgensztern D; Liu SV; Cho BC; Bazhenova L; Rodriguez CP; Doebele RC; Wozniak A; Reckamp KL; Seery T; Nikolinakos P; Hu Z; Oliver JW; Trone D; McArthur K; Patel R; Multani PS; Ahn MJ
    Cancer Discov; 2019 Mar; 9(3):384-395. PubMed ID: 30487236
    [No Abstract]   [Full Text] [Related]  

  • 34. Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.
    Yang J; Chen K; Zhang G; Yang QY; Li YS; Huang SZ; Wang YL; Yang W; Jiang XJ; Yan HX; Zhu JQ; Xiang R; Luo YF; Li WM; Wei YQ; Li LL; Yang SY
    Eur J Med Chem; 2018 Jan; 143():1148-1164. PubMed ID: 29133048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target.
    Laxmi A; Gupta P; Gupta J
    Cancer Biomark; 2019; 24(4):383-393. PubMed ID: 30909182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KIF5B-RET fusions in lung adenocarcinoma.
    Kohno T; Ichikawa H; Totoki Y; Yasuda K; Hiramoto M; Nammo T; Sakamoto H; Tsuta K; Furuta K; Shimada Y; Iwakawa R; Ogiwara H; Oike T; Enari M; Schetter AJ; Okayama H; Haugen A; Skaug V; Chiku S; Yamanaka I; Arai Y; Watanabe S; Sekine I; Ogawa S; Harris CC; Tsuda H; Yoshida T; Yokota J; Shibata T
    Nat Med; 2012 Feb; 18(3):375-7. PubMed ID: 22327624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drosophila Cancer Models Identify Functional Differences between Ret Fusions.
    Levinson S; Cagan RL
    Cell Rep; 2016 Sep; 16(11):3052-3061. PubMed ID: 27626672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenvatinib Induces AKT/NF-κB Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung Cancer
    Liu YC; Hsu FT; Chung JG; Weng MC; Ting CY; Tsai CJ; Lan A; Wu JY; Lin CC; Lin SS
    Anticancer Res; 2021 Jun; 41(6):2867-2874. PubMed ID: 34083277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma.
    Ciampi R; Giordano TJ; Wikenheiser-Brokamp K; Koenig RJ; Nikiforov YE
    Endocr Relat Cancer; 2007 Jun; 14(2):445-52. PubMed ID: 17639057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.